Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entest Group Inc ETNI

Financial Services Industrials Conglomerates
Entest Group Inc is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. The Company’s current business plan is to seek new business opportunities or to engage in a business combination with an unidentified company. The... see more

Recent & Breaking News (GREY:ETNI)

    Entest Group, Inc. Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc.

    PR Newswire May 10, 2018

    Entest BioMedical Inc. Announces 3 Million Share Zander Therapeutics, Inc. Dividend to be Paid to Shareholders

    PR Newswire September 29, 2017

    Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board

    PR Newswire September 13, 2017

    Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immune Suppression of IL-17a and IL-2 in Dogs With Novel NR2F6 Activators

    PR Newswire July 26, 2017

    Zander Therapeutics Inc. Announces Brian Devine, Former Chairman of PETCO, to Helm its Business Advisory Board

    PR Newswire June 27, 2017

    Entest BioMedical's Subsidiary Zander Therapeutics, Inc., Reports Its Series A Compounds Suppressed the Production of Multiple Cytokines Known to be Involved in Inflammation With No Toxicity In Canine Studies

    PR Newswire June 13, 2017

    Entest BioMedical's Subsidiary Zander Therapeutics, Inc. Reports on Preliminary Canine Experiments Testing New Anti-Inflammatory Drug Compounds

    PR Newswire June 7, 2017

    Entest BioMedical, Inc. Settles $841,531 of Principal Indebtedness Through the Issuance of Equity Securities

    PR Newswire May 31, 2017

    Entest BioMedical Inc. Subsidiary Zander Therapeutics Discusses Developments in Medicinal Chemistry for Veterinary Applications of Cancer and Autoimmune Therapies Through Modulation of Checkpoint NR2F6

    PR Newswire May 23, 2017

    Entest BioMedical's Chairman Discusses its Subsidiary, Zander Therapeutics, Inc.'s Progress With Small Molecule Immunotherapies for Treating Cancer and Arthritis in Dogs

    PR Newswire April 26, 2017

    Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Announces Appointment of Dr. Thomas Donnelly to Serve as Senior Veterinary Advisor

    PR Newswire March 9, 2017

    Entest BioMedical Inc.'s Zander Therapeutics Unit Announces Publication of Canine Cellular Immunotherapy Patent Application for Treating Cancer in Dogs

    PR Newswire February 15, 2017

    Entest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications

    PR Newswire October 19, 2016

    Entest BioMedical Updates Company Status and Future Plans

    PR Newswire September 24, 2015

    Entest BioMedical's Zander Therapeutics Unit Files Patent Application on Ex Vivo Activated Autologous Immune Cells

    PR Newswire August 11, 2015

    Entest BioMedical Inc.'s Zander Therapeutics Unit: Initial Focus is Small Molecule and Cancer Stem Targeting for Veterinary Oncology

    PR Newswire August 3, 2015

    Entest BioMedical, Inc. in Discussions to Acquire Nanotechnology Delivery System for Cancer Therapy

    Marketwired June 1, 2015

    Entest BioMedical Inc. Recruits Salk Institute Researcher to Lead Cancer Stem Cell Program for Treating Feline Leukemia and Canine Cancer

    Marketwired July 16, 2014